Table 4. Comparison between morphological phenotype, genotype, grading and survival.

Morphological phenotype	Conventional ductal adenocarcinoma (without components) (A1)	Combined ductal adenocarcinoma (with additional components) (A2)	Variants (B)
N	91	72	14
KRAS
Wildtype	7	3	3
Mutated	84	69	11
p-value A1 vs A21	0.35
p-value A vs B1	0.035
CDKN2A/p16
Intact	29	11	3
Altered	62	60	11
p-value A1 vs A21	0.016
p-value A vs B1	0.78
TP53
Intact	22	11	5
Altered	69	61	9
p-value A1 vs A21	0.16
p-value A vs B1	0.17
SMAD4
Intact	57	45	10
Altered	34	27	4
p-value A1 vs A21	0.98
p-value A vs B1	0.51
Number of mutations
0	0	0	1
1	5	1	2
2	30	14	3
3	40	40	5
4	16	17	3
p-value A1 vs A21	0.09
p-value A vs B1	0.004
Pathologic stage
Primary tumour
T1	2	2	0
T2	3	8	0
T3	74	55	14
T4	12	7	0
p-value A1 vs A21	0.23
p-value A vs B1	0.55
Nodal status
N0	24	22	7
N1	67	50	7
p-value A1 vs A21	0.60
p-value A vs B1	0.12
Grading
G1	7	1	5
G2	4	27	6
G3	44	44	3
p-value A1 vs A21	0.08
p-value A vs B1	<0.001
Survival
(months)	22.7	15.5	34.1
p-value A1 vs A22	0.07
p-value A vs B2	0.06

¹ Chi²-test/Fisher’s exact test, ²Log-rank-test.